Eli Lilly could appeal to both growth and income-oriented investors.

By Sneha S K May 8 (Reuters) - Eli Lilly's new weight-loss pill, Foundayo, was prescribed 7,335 times in the U.S. in the ...

While Pfizer is playing catch-up in the GLP-1 race, it has several irons in the fire that could turn its business around.

Early data from weight-loss pills are lifting shares in Novo Nordisk and Eli Lilly as investors bet that easier-to-take drugs ...

Eli Lilly leads GLP-1s but faces rising Novo competition; DCF fair value is $956 vs. $960. Click here to read this latest ...

Eli Lilly and Co. LLY revealed plans to inject an extra $4.5 billion into two of its Indiana manufacturing sites on Wednesday ...

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of ...

Mounjaro generated $8.66 billion in sales in the first quarter.

Eli Lilly is a leader in one of today’s biggest growth markets: weight loss drugs. The company recently won approval for an ...

With commitments to invest more than $50 billion in building up its U.S. manufacturing presence, Eli Lilly has earmarked an ...

From mass-producing insulin to building pharmaceutical AI “factories,” Lilly’s 150-year North Star remains the same: being in ...

Lilly hiked its full-year sales outlook by $2 billion, and also raised its adjusted profit guidance.